Belay Diagnostics Reports Strong Clinical Utility for Summit 2.0
CHICAGO, July 21, 2026 Belay Diagnostics has announced the publication of a peer-reviewed clinical utility study demonstrating that its...
Genomic Testing
Advertisement
GRAIL Teams with Priority Health to Expand Galleri
MENLO PARK, Calif., July 16, 2026 GRAIL, Inc. has announced a strategic collaboration with Priority Health, making the Galleri®...
PreludeDx Expands DCIS Education Through New Collaboration
LAGUNA HILLS, Calif., July 7, 2026 PreludeDx™, a leader in precision diagnostics for early-stage breast cancer, has announced a...
Arima Genomics Reports Hi-C Outperforms Whole Genome Sequencing
CARLSBAD, Calif., June 11, 2026 Arima Genomics, a cancer diagnostics company focused on integrating DNA sequence and genome structure...
Veracyte Highlights Practice-Changing Cancer Test Data at ASCO 2026
SOUTH SAN FRANCISCO, California, 21 May 2026 Veracyte, Inc. announced that major Phase III clinical trial results involving its...
Advertisements
Datar Cancer Genetics Receives Landmark FDA Approval for CellDx-Tissue
NASHIK, India, May 21, 2026 Datar Cancer Genetics (DCG) has achieved a major milestone in precision oncology after receiving...
Caris Life Sciences Files NY Approval for Caris Assure
IRVING, Texas, May 8, 2026 Caris Life Sciences® has submitted an application to the New York State Department of...
Myriad CDx Test Approved to Guide Ovarian Cancer Therapy
SALT LAKE CITY, March 17, 2026 Myriad Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
mdxhealth Showcases GPS Test Advancing Prostate Care
Irvine, California, March 16, 2026 mdxhealth SA announced new clinical data from the ProMPT study led by the University...
Retevmo Shows Strong Survival Benefit in RET+ Lung Cancer
INDIANAPOLIS, Feb. 16, 2026 — Eli Lilly and Company announced positive Phase III results demonstrating that Retevmo® (selpercatinib) delivered...
Advertisement
